CompletedPhase 1

Clinical Study of DMT in Healthy Adults

Brazil27 participantsStarted 2022-06-01

Plain-language summary

This study aims to evaluate the acute and subacute effects of an inhaled N, N-Dimethyltryptamine in healthy individuals.

Who can participate

Age range

18 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * prior experience with N,N-Dimethyltryptamine (DMT) * present proof of vaccination against COVID-19 (Coronavírus) Exclusion Criteria: * heart failure * liver failure * kidney failure * resistant hypertension * arrhythmia * valvular heart disease * chronic obstructive pulmonary disease * asthma * severe obesity * epilepsy * pregnancy * thyroid disorders * family diagnosis or suspicion of genetic monoamine oxidase deficiency * previous adverse response to psychedelic substances * present or past symptoms or family members with a psychotic disorder * dissociative identity disorder * bipolar disorder * prodromal symptoms of schizophrenia * abuse of alcohol or other psychoactive substances, except tobacco * acute or sub-acute risk of suicide * flu-like symptoms

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Incidence of Treatment-Emergent Adverse Events as clinical and psychiatry symptoms assessed by qualitative medical/clinical-psychiatry evaluation

Timeframe: up to 1 month after dosing

Blood Pressure

Timeframe: up to 2 hours after each dose

Heart rate

Timeframe: up to 2 hours after each dose

Respiratory rate

Timeframe: up to 2 hours after each dose

Oxygen saturation

Timeframe: up to 2 hours after each dose

Trial details

NCT IDNCT05573568

SponsorBiomind Labs Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-11-01

View on ClinicalTrials.gov More Healthy Volunteers trials

Who can participate

Age range

18 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Incidence of Treatment-Emergent Adverse Events as clinical and psychiatry symptoms assessed by qualitative medical/clinical-psychiatry evaluation

Timeframe: up to 1 month after dosing

Blood Pressure

Timeframe: up to 2 hours after each dose

Heart rate

Timeframe: up to 2 hours after each dose

Respiratory rate

Timeframe: up to 2 hours after each dose

Oxygen saturation

Timeframe: up to 2 hours after each dose